Market Growth Analysis:
The global PDX models market is expected to reach to USD 167.6 Million by 2022 from USD 68.0 Million in 2016 at a CAGR of 16.7%. The growth of the overall Patient Derived Xenograft Models Market can be attributed to the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121598251
Objectives Of Study:
1. To define, describe, and measure the global Patient Derived Xenograft (PDX) models market by model type, tumor type, application, end user, and region
2. To provide detailed information regarding the major factors, such as drivers, restraints, growth opportunities, and challenges influencing the growth of the market
3. To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the global PDX models market
Growing Application Driving Growth In PDX Models Market:
In 2017, the preclinical drug development and basic cancer research segment is expected to account for the largest share of the global patient derived xenograft models market. Growth in this segment is mainly driven by the increasing number of research activities in the field of oncology drug research. On the basis of end user, the PDX models market has been segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic & research institutions. The pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the patient derived xenograft models market in 2017. The large share of this segment is due to the increasing expenditure on R&D by companies for drug development.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=121598251
Key Players in PDX Models Market:
The various players in the global PDX models industry include Crown Bioscience Inc. (US), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), ONCODESIGN (France), Charles River Laboratories International, Inc. (US), EPO Berlin-Buch GmBH (Germany), Shanghai LIDE Biotech Co., Ltd (China), Xentech (France), Horizon Discovery Group PLC (UK), Urolead (France), and Explora BioLabs (US).
